CASI: יחס מחיר לרווח לקצב צמיחה CASI Pharmaceuticals, Inc

CASI Pharmaceuticals' expansion in the US and China to implement Western oncology drugs is driving price action. The peg_co multiple reflects the impact of EVOMELA sales and the development of new antibodies. Meanwhile, 0.00 serves as the parameter's baseline value, confirming the efficiency of the licensing model via contract manufacturing organizations (CMO), which minimizes capital expenditures and operational business risks.

Assessing asset quality requires comparing market value with actual profit dynamics. The PEG ratio measures the P/E ratio relative to growth rates, where a value below one signals that the business is undervalued. By analyzing the historical P/E-to-growth dynamics on GURU.Markets, an investor can see the current level of 0.00. This allows for an evaluation of the effectiveness of the oncology R&D pipeline of CASI Pharmaceuticals (CASI). The potential for profit growth from the implementation of targeted inhibitors determines the company's investment attractiveness.